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The applicative potential of synthetic calcium phosphates, especially hydroxyapatite (HAp), has 
become intensely broadened in the past 10 years, from bone tissue engineering to multiple other 
fields of biomedicine. Previously we have shown that hydroxyapatite nanoparticles coated with 
chitosan-poly(D,L)-lactide-co-glycolide (HAp/Ch-PLGA) target lungs following their intravenous 
administration into mice. For this purpose radioactive 125-Iodine (125I), a low energy gamma 
emitter, was used to develop a novel in situ method for radiolabeling of particles and investigation 
of their biodistribution. 
In this study we utilize an emulsification process and freeze drying to load the composite particles 
based on hydroxyapatite nanocarrier, chitosane and poly(lactic-co-glycolic acid) with 17β-
hydroxy-17α-picolyl-androst-5-en-3β-acetate (A), a chemotherapeutic derivative of androstane. 
The picolyl androstane derivatives showed high potency in the cell inhibitors of hormone-
dependent cancers (adenocarcinoma, prostate cancer, cervix carcinoma, colon cancer, etc.). 
1H NMR, 13C NMR and high-resolution time-of-flight mass spectrometry (MS) techniques 
confirmed the intact structure of the derivative A following its entrapment within HAp/Ch-PLGA 
particles. The synthesized particles of A-loaded HAp/Ch-PLGA were found to be spherical in 
shape with a uniform size distribution of d50=168 nm. The release of A from HAp/Ch-PLGA was 
sustained, with no burst release or plateauing after three weeks. The obtained results of the DET 
and MTT tests show that the particles of A-loaded HAp/Ch-PLGA exhibit almost three times 
higher cytotoxicity towards lung adenocarcinoma cells (A549) than towards healthy cells 
(MRC5), while at the same time allowing twice as fast recovery of healthy cells. We have also 
analyzed the period of recovery of healthy, as well as cancer cells, following the treatment with 
A-loaded HAp/Ch-PLGA. After treatment with A-loaded HAp/Ch-PLGA, healthy cells recover 
twice as fast as the malignant ones. Immunofluorescent staining of primary fibroblasts interacting 
with HAp/Ch-PLGA and A-HAp/Ch-PLGA particles demonstrates no negative morphological or 
proliferative effects on cells. 
